TransMedics Group (NASDAQ:TMDX) Trading 9.6% Higher on Analyst Upgrade

TransMedics Group, Inc. (NASDAQ:TMDXGet Rating) was up 9.6% during mid-day trading on Friday after Oppenheimer raised their price target on the stock from $40.00 to $45.00. Oppenheimer currently has an outperform rating on the stock. TransMedics Group traded as high as $45.38 and last traded at $45.17. Approximately 25,164 shares were traded during trading, a decline of 93% from the average daily volume of 374,697 shares. The stock had previously closed at $41.21.

TMDX has been the subject of a number of other reports. JPMorgan Chase & Co. raised TransMedics Group from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $26.00 to $48.00 in a research note on Tuesday. Canaccord Genuity Group increased their target price on TransMedics Group from $46.00 to $58.00 in a research note on Thursday. Cowen increased their target price on TransMedics Group from $45.00 to $50.00 in a research note on Tuesday. Cowen raised their price target on shares of TransMedics Group from $39.00 to $45.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 26th. Finally, Morgan Stanley raised their price target on shares of TransMedics Group from $34.00 to $37.00 and gave the stock an “equal weight” rating in a research note on Wednesday. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, TransMedics Group has a consensus rating of “Moderate Buy” and a consensus price target of $46.00.

Insider Activity

In other news, Director James R. Tobin sold 48,515 shares of the stock in a transaction that occurred on Tuesday, July 5th. The stock was sold at an average price of $35.00, for a total value of $1,698,025.00. Following the completion of the sale, the director now owns 302,106 shares of the company’s stock, valued at approximately $10,573,710. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other TransMedics Group news, VP John F. Carey sold 1,500 shares of the firm’s stock in a transaction on Wednesday, June 1st. The stock was sold at an average price of $28.19, for a total transaction of $42,285.00. Following the completion of the sale, the vice president now owns 379 shares of the company’s stock, valued at approximately $10,684.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director James R. Tobin sold 48,515 shares of the firm’s stock in a transaction on Tuesday, July 5th. The shares were sold at an average price of $35.00, for a total value of $1,698,025.00. Following the sale, the director now directly owns 302,106 shares of the company’s stock, valued at approximately $10,573,710. The disclosure for this sale can be found here. In the last 90 days, insiders sold 151,814 shares of company stock valued at $5,633,336. 8.70% of the stock is owned by insiders.

Institutional Investors Weigh In On TransMedics Group

Several hedge funds have recently added to or reduced their stakes in the business. Sandhill Capital Partners LLC lifted its holdings in shares of TransMedics Group by 25.4% during the fourth quarter. Sandhill Capital Partners LLC now owns 1,805,518 shares of the company’s stock worth $34,594,000 after buying an additional 365,473 shares in the last quarter. Kornitzer Capital Management Inc. KS lifted its holdings in shares of TransMedics Group by 9.6% during the first quarter. Kornitzer Capital Management Inc. KS now owns 512,284 shares of the company’s stock worth $13,801,000 after buying an additional 45,000 shares in the last quarter. Emerald Advisers LLC lifted its holdings in shares of TransMedics Group by 41.5% during the second quarter. Emerald Advisers LLC now owns 397,565 shares of the company’s stock worth $12,503,000 after buying an additional 116,612 shares in the last quarter. Portolan Capital Management LLC acquired a new stake in shares of TransMedics Group during the first quarter worth $10,233,000. Finally, Emerald Mutual Fund Advisers Trust lifted its holdings in shares of TransMedics Group by 27.5% during the second quarter. Emerald Mutual Fund Advisers Trust now owns 347,349 shares of the company’s stock worth $10,924,000 after buying an additional 74,944 shares in the last quarter. Institutional investors and hedge funds own 71.75% of the company’s stock.

TransMedics Group Stock Up 18.4 %

The company has a debt-to-equity ratio of 0.59, a current ratio of 5.22 and a quick ratio of 4.40. The company has a market cap of $1.36 billion, a P/E ratio of -28.36 and a beta of 1.63. The stock has a 50-day moving average of $32.37 and a 200 day moving average of $25.13.

TransMedics Group (NASDAQ:TMDXGet Rating) last issued its quarterly earnings results on Monday, August 1st. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.09). TransMedics Group had a negative return on equity of 69.38% and a negative net margin of 92.76%. During the same period in the prior year, the firm posted ($0.39) earnings per share. Research analysts anticipate that TransMedics Group, Inc. will post -1.58 earnings per share for the current year.

About TransMedics Group

(Get Rating)

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Featured Stories

Want More Great Investing Ideas?

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.